• Publications
  • Influence
Thirty Years of the Drug Candidate NAMI‐A and the Myths in the Field of Ruthenium Anticancer Compounds: A Personal Perspective
As anticipated in the title, this contribution is basically divided into two, strictly connected, parts. The first is a personal overview of the ruthenium drug candidate NAMI-A, almost 30 years after
A categorization of metal anticancer compounds based on their mode of action.
A categorization of metal anticancer compounds into five classes based on their mode of action is suggested, that is clearly focused on the metal compound and is independent from the nature of its bio-target(s)-most often still unknown-has the purpose of providing an intellectual tool that might be helpful in the rational development of new drugs.
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy
Main adverse events consisted of neutropenia, anemia, elevated liver enzymes, transient creatinine elevation, nausea, vomiting, constipation, diarrhea, fatigue, and renal toxicity.
Ruthenium antimetastatic agents.
This review article focuses on the development of new classes of ruthenium complexes originated from the NAMI-A frame, found to have antimetastatic activity comparable to, or even better than, Nami-A; however, the nature of the target(s) responsible for the antimetASTatic activity remains unclear.
NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry
A critical and strictly comparative analysis of the studies conducted so far on NAMI-A and KP1019 allows us to define the state of the art of these experimental ruthenium drugs in terms of the respective pharmacological profiles and potential clinical applications, and to gain some insight into the inherent molecular mechanisms.
Bioinorganic medicinal chemistry
MEDICINAL INORGANIC CHEMISTRY: STATE OF THE ART, NEW TRENDS, AND A VISION OF THE FUTURE Introduction Antimicrobial Agents Antiviral Agents Systemic and Metabolic Diseases Including Inflammation Metal
Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex
The replacement of Na+ with ImH+ therefore, besides the better chemical stability of the molecule, confers to [trans-RuCl4 (DMSO)Im] - a closer similarity with a true drug to be used in humans, and suggests this molecule for future studies of preclinical toxicology and phase I and II clinical trials.
Synthesis, molecular structure, and chemical behavior of hydrogen trans-bis(dimethyl sulfoxide)tetrachlororuthenate(III) and mer-trichlorotris(dimethyl sulfoxide)ruthenium(III): the first fully
The synthesis, molecular structure and chemical behavior of two chloride-dimethyl sulfoxide-ruthenium (III) derivatives, namely [(DMSO) 2 H][trans-Ru(DMSO) 2 Cl 4 ] (1) and mer-Ru(DMSO) 3 Cl 3 (2),
DNA as a possible target for antitumor ruthenium(III) complexes.
It was found that both ruthenium(III) antitumor complexes slightly alter DNA conformation, modify its electrophoretic mobility, and inhibit DNA recognition and cleavage by some restriction enzymes, though they were less effective than cisplatin in producing such effects.
Down‐regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an anti‐metastatic ruthenium complex
The different enzyme/inhibitor mRNA levels between untreated and treated tumours seem to be unaffected by tumour‐infiltrating lymphocytes and are paralleled by the maintenance of connective tissue around blood vessels in the tumour mass.